CK Life Sciences International (0775) will present new data from preclinical studies of investigational cancer vaccines at the American Association for Cancer Research's annual meeting in Chicago this week.
The cancer vaccines target PRAME (preferentially expressed antigen in melanoma), PD-L1 (programmed cell death ligand 1), B7-H3 (B7 homolog 3) and Claudin 6 proteins.
In addition, the company will co-present with its research collaborator two posters showcasing their artificial intelligence-empowered platform for designing cancer vaccines at the meeting, which runs from April 25 to 30 in the US city.
CK Life vice president and chief scientific officer Melvin Toh Kean-meng revealed the company currently has a number of therapeutic cancer vaccines in clinical and discovery/preclinical stages.
STAFF REPORTER
